CryoPort, Inc. (NASDAQ:CYRX) Receives Average Recommendation of “Moderate Buy” from Brokerages

CryoPort, Inc. (NASDAQ:CYRX) has received a consensus recommendation of “Moderate Buy” from the ten brokerages that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and eight have given a buy recommendation to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $12.9444.

Several analysts have recently issued reports on CYRX shares. Wall Street Zen cut CryoPort from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. Needham & Company LLC boosted their price target on shares of CryoPort from $12.00 to $13.00 and gave the stock a “buy” rating in a research report on Wednesday, March 4th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of CryoPort in a research note on Monday, December 29th.

Insider Transactions at CryoPort

In other news, CFO Robert Stefanovich sold 38,700 shares of the company’s stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $7.76, for a total transaction of $300,312.00. Following the sale, the chief financial officer directly owned 255,701 shares in the company, valued at approximately $1,984,239.76. This represents a 13.15% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Mark W. Sawicki sold 3,235 shares of the stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $8.00, for a total transaction of $25,880.00. Following the completion of the transaction, the insider directly owned 103,697 shares of the company’s stock, valued at approximately $829,576. The trade was a 3.03% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 54,610 shares of company stock worth $427,592 in the last three months. Insiders own 10.10% of the company’s stock.

Institutional Investors Weigh In On CryoPort

Several institutional investors have recently modified their holdings of CYRX. Mak Capital One LLC bought a new position in shares of CryoPort during the 3rd quarter valued at approximately $7,756,000. UBS Group AG lifted its position in CryoPort by 112.7% in the third quarter. UBS Group AG now owns 1,331,521 shares of the company’s stock worth $12,623,000 after buying an additional 705,649 shares during the last quarter. Millennium Management LLC boosted its stake in CryoPort by 23.8% during the fourth quarter. Millennium Management LLC now owns 3,244,802 shares of the company’s stock worth $31,150,000 after buying an additional 623,896 shares during the period. Kennedy Capital Management LLC purchased a new position in CryoPort during the second quarter worth $4,084,000. Finally, Assenagon Asset Management S.A. increased its position in CryoPort by 37.4% during the third quarter. Assenagon Asset Management S.A. now owns 1,498,774 shares of the company’s stock valued at $14,208,000 after acquiring an additional 408,263 shares during the last quarter. 92.90% of the stock is owned by institutional investors.

CryoPort Trading Down 3.0%

Shares of CYRX stock opened at $8.04 on Monday. The stock has a market capitalization of $400.87 million, a price-to-earnings ratio of 6.09 and a beta of 1.69. CryoPort has a 12-month low of $4.63 and a 12-month high of $11.45. The stock’s 50-day moving average price is $9.05 and its 200-day moving average price is $9.35.

CryoPort (NASDAQ:CYRX) last announced its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). The firm had revenue of $45.45 million for the quarter, compared to the consensus estimate of $42.92 million. CryoPort had a net margin of 42.35% and a negative return on equity of 8.22%. As a group, research analysts predict that CryoPort will post -0.99 EPS for the current fiscal year.

About CryoPort

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.